Overview

Study Evaluating Duvelisib in Japanese Subjects With Relapsed or Refractory Lymphoma

Status:
Completed
Trial end date:
2017-02-01
Target enrollment:
Participant gender:
Summary
This study seeks to evaluate the safety and pharmacokinetics of duvelisib in Japanese participants with relapsed or refractory lymphoma.
Phase:
Phase 1
Details
Lead Sponsor:
AbbVie
Collaborator:
Infinity Pharmaceuticals, Inc.